From Assisted Hatching to Embryo Glue, Most IVF ‘Add-ons’ Rest on Shaky Science, Studies Find
By Sharon Begley,
STAT
| 11. 05. 2019
By the time Sarah Chamberlin’s fertility doctor declared her genes “incompatible” with her husband’s and said the clash might be preventing her from having children, she’d had five rounds of artificial insemination and two cycles of in vitro fertilization — and precisely zero pregnancies. So when the physician suggested she try a drug that is ordinarily prescribed to cancer patients, to get her immune system to stop attacking her embryos, she didn’t hesitate.
“I was 41 by then,” said Chamberlain, 47, who lives on New York’s Long Island and at the time was a consultant at her husband’s restaurant. “When they say they have one more thing you can try, it gives you hope.”
She had already spent tens of thousands of dollars in an effort to conceive — her insurance didn’t cover assisted reproduction — and had grown inured to the fertility-related shots that turned her into a human pin cushion. With all she had been through, it seemed foolish to hesitate over six additional daily injections and another $3,000 for the drug, called Neupogen; the idea that she... see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...